Skip to main content
. 2015 Apr 23;33(5):1390–1404. doi: 10.1002/stem.1926

Figure 5.

Figure 5

Retinoic acid (RA) signalling in EpiSC reprogramming. (A): RA signalling as measured by a luciferase assay in EpiSCs cultured in N2B27/activin/FGF2 with VA and other retinoids. The activities are shown relative to that of Renilla luciferase and normalized to that of EpiSCs in −VA. (B): A diagram of EpiSC reprogramming in 2i/LIF. (C): The effects of retinoids on reprogramming Oct4‐GFP reporter EpiSCs to induced pluripotent stem cells by LRH1. *, p < .05; **, p < .01. Scale bar = 200 µm. (D): RA signalling at various stages of EpiSC reprogramming. **, p < .01. (E): The effects of expressing RARG (under the CMV early enhancer/chicken β actin promoter) on reprogramming EpiSCs by LRH1. Note that even small amounts of Rarg PB transposon have deleterious effects. *, p < .05; **, p < .01. (F): Blocking LRH1‐mediated EpiSC reprogramming by ligand depletion (citral), RA receptor inhibition (CD2665) or expression of RARA‐DN. Reprogramming was partially restored by 0.1 nM ATRA. Oct4‐GFP+ colonies were scored on day 9 after transfection. *, p < .05; **, p < .01. In all the experiments, Oct4‐GFP+ colonies were scored on day 9 after transfection. The experiments were repeated at least three times, and the error bars show standard deviations from the mean of triplicate determinations in one representative experiment. Abbreviations: ATRA, all‐trans retinoic acid; 9cRA, 9‐cis‐retinoic acid; EpiSCs, epiblast stem cells; FGF2, fibroblast growth factor 2; LIF, leukemia inhibitory factor; LRH1, liver receptor homolog‐1; RARA‐DN, dominant‐negative form of RARA; RARG, retinoic acid receptor gamma; VA, vitamin A.